In a Transformative Year, Vertex Advances Its Commitment to Corporate Responsibility; Announces 2023 CR Report

Apr 25, 2024 8:30 AM ET

2023 was a transformative year for Vertex. The company made significant advances toward delivering on its core mission of creating transformative medicines for people with serious diseases and ushering in a new era of diversification. Vertex’s differentiated strategy, investment in scientific innovation, and unique culture have enabled the company to extend its leadership in cystic fibrosis, expand into new disease areas with the regulatory approvals of CASGEVY™ (exagamglogene autotemcel), rapidly advance its robust research and development (R&D) pipeline, and drive positive impact for patients, employees and its communities. The company remains committed to making a difference — for patients and families impacted by serious diseases, for its communities, and for each other. Vertex’s differentiated strategy and unique culture, along with its drive and dedication, will fuel the company’s ability to deliver results and operate its business responsibly.

About Vertex 
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X. 

Media Contact:
Sarah D’Souza, 857-329-8495

Read More